Tripep submits new application for phase II study of ChronSeal®

Tripep submits new application for phase II study of ChronSeal®

Tripep has submitted a new application to the Medical Products Agency concerning
the initiation of a Phase II study of ChronSeal®, a product owned jointly by
Tripep and Kringle Pharma for the treatment of chronic leg wounds. The renewed
application contains among other things supplementary information requested by
the Medical Products Agency regarding the production of HGF (hepatocyte growth
factor) in Japan. An independent inspection of the Japanese production facility
has been performed as well as a revision of the study protocol. If approval is
granted, it is estimated that the study will start during the fourth quarter of
2008.

For more information, please contact:
Jan Nilsson, CEO, Tripep AB		                         
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63               
E-mail: jan.nilsson@tripep.se		                         

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


 About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's website: www.tripep.se.
About ChronSeal® 
ChronSeal® is a HGF-based (Hepatocyte Growth Factor) treatment for chronic leg
wounds, a rapidly increasing problem among the elderly population of the Western
World. In cooperation with Tripep's partners Kringle Pharma and Zelmic AB, a new
formulation has been developed that enables the use of ChronSeal® without it
being combined with antibiotics. The new formulation allows for controllable
release of HGF, thus avoiding antibiotic resistance, another rapidly growing
problem. An application for a patent pertaining to an antibiotic-free
formulation of ChronSeal® was filed in the US in January 2008. 

More than four million people in the US and Europe are currently suffering from
chronic leg wounds. According to Epsicom Business Intelligence this corresponds
to a market value of approximately SEK 24 billion. Accordingly, the medical need
is considerable and the growth rate is high, factors that are expected to
provide ChronSeal® with substantial commercial potential.